Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
09/30/2023 | 06/30/2023 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | -- | -- | |||
Gross Profit | -- | -- | |||
SG&A Expenses | -26.69% | -13.57% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | -23.97% | -21.29% | |||
Operating Income | 23.97% | 21.29% | |||
Income Before Tax | 22.79% | 18.90% | |||
Income Tax Expenses | 200.00% | 0.00% | |||
Earnings from Continuing Operations | 22.76% | 18.89% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | 22.76% | 18.89% | |||
EBIT | 23.97% | 21.29% | |||
EBITDA | 27.75% | 23.77% | |||
EPS Basic | 37.35% | 38.10% | |||
Normalized Basic EPS | 37.39% | 38.10% | |||
EPS Diluted | 37.35% | 38.10% | |||
Normalized Diluted EPS | 37.39% | 38.10% | |||
Average Basic Shares Outstanding | 23.32% | 31.01% | |||
Average Diluted Shares Outstanding | 23.32% | 31.01% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |